{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:14Z","timestamp":1790456294111,"version":"4.1.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In 2026, the fourth edition of the evidence-based clinical practice guidelines for peptic ulcer disease by the Japanese Society of Gastroenterology (JSGE) was revised. These revised guidelines cover epidemiology, hemorrhagic peptic ulcers,\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    eradication therapy, non-eradication therapy, drug-induced ulcers, non\n                    <jats:italic>-H. pylori<\/jats:italic>\n                    , and nonsteroidal anti-inflammatory drug (NSAID) ulcers, remnant gastric ulcers, surgical treatment, and conservative therapy for perforation and stenosis. Although\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection and NSAIDs use remain two major causes of peptic ulcers, the prevalence and mortality rates of peptic ulcer have been declining due to the widespread use of eradication therapy and development of potent acid-inhibitory drugs in recent years. However, an increasing trend in idiopathic ulcers and ulcers caused by non-\n                    <jats:italic>H. pylori Helicobacter<\/jats:italic>\n                    (NHPH) infection has attracted attention. In this revised edition, therapeutic algorithms for the treatment of peptic ulcers based on\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection, low-dose aspirin (LDA) or NSAID use, ulcer history, and ulcer complications (e.g., hemorrhage) remain largely unchanged. This edition shows options for\n                    <jats:italic>H. pylori<\/jats:italic>\n                    eradication in various situations compared with the previous edition, and recommends the most effective regimens, regardless of Japanese insurance coverage. In addition, a new flowchart outlining the eradication treatment process has been presented. Compared with the previous version, the main changes in pharmacological treatment have been made: due to its acid-inhibitory characteristics compared with proton pump inhibitors and increased evidence of its efficacy and safety, vonoprazan has now been selected as the first-line treatment for peptic ulcers and NSAID- and LDA-induced ulcers.\n                  <\/jats:p>","DOI":"10.1007\/s00535-026-02504-3","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:20:26Z","timestamp":1787559626000},"page":"1361-1381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence-based clinical practice guidelines for peptic ulcer disease 2026"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-7392","authenticated-orcid":false,"given":"Mitsushige","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoari","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Murao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sunago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hourin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Chinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Higashimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hirashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Miyamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Mukohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Itoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2504_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12415","author":"M Tsuda","year":"2017","unstructured":"Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017. https:\/\/doi.org\/10.1111\/hel.12415.","journal-title":"Helicobacter"},{"issue":"4","key":"2504_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","volume":"56","author":"T Kamada","year":"2020","unstructured":"Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2020;56(4):303\u201322.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2504_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00535-014-1016-1","volume":"50","author":"M Yoshida","year":"2014","unstructured":"Yoshida M, Kinoshita Y, Watanabe M, Sugano K. JSGE clinical practice guidelines 2014: standards, methods, and process of developing the guidelines. J Gastroenterol. 2014;50(1):4\u201310.","journal-title":"J Gastroenterol"},{"issue":"6","key":"2504_CR4","volume":"2013","author":"I Neumann","year":"2013","unstructured":"Neumann I, Letelier LM, Rada G, Claro JC, Martin J, Howden CW, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013;2013(6):CD007999.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2504_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/bcp.12866","volume":"82","author":"Z Jian","year":"2016","unstructured":"Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? Meta-analysis of the published literature. Br J Clin Pharmacol. 2016;82(3):880\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2504_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5152\/tjg.2018.17143","volume":"29","author":"G Sgourakis","year":"2018","unstructured":"Sgourakis G, Chatzidakis G, Poulou A, Malliou P, Argyropoulos T, Ravanis G, et al. High-dose vs. low-dose proton pump inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer. A meta-analysis and meta-regression analysis. Turk J Gastroenterol. 2018;29(1):22\u201331.","journal-title":"Turk J Gastroenterol"},{"issue":"4","key":"2504_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1053\/j.gastro.2024.03.036","volume":"167","author":"T Geeratragool","year":"2024","unstructured":"Geeratragool T, Kaosombatwattana U, Boonchote A, Chatthammanat S, Preechakawin N, Srichot J, et al. Comparison of vonoprazan versus intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial. Gastroenterology. 2024;167(4):778-87 e3.","journal-title":"Gastroenterology"},{"key":"2504_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123606","author":"T Pattarapuntakul","year":"2024","unstructured":"Pattarapuntakul T, Wong T, Wetwittayakhlang P, Netinatsunton N, Keeratichananont S, Kaewdech A, et al. Efficacy of vonoprazan vs. intravenous proton pump inhibitor in prevention of re-bleeding of high-risk peptic ulcers: a randomized controlled pilot study. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13123606.","journal-title":"J Clin Med"},{"key":"2504_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/tgh-2025-159","volume":"11","author":"M Sugimoto","year":"2026","unstructured":"Sugimoto M, Murata M. Differences and trends in worldwide clinical guidelines for Helicobacter pylori infection. Transl Gastroenterol Hepatol. 2026;11:47.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"9","key":"2504_CR10","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","volume":"99","author":"AC Ford","year":"2004","unstructured":"Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99(9):1833\u201355.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2504_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","volume":"12","author":"M Sugimoto","year":"2007","unstructured":"Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317\u201323.","journal-title":"Helicobacter"},{"issue":"10","key":"2504_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048\u201359.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2504_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439\u201346.","journal-title":"Gut"},{"key":"2504_CR14","doi-asserted-by":"crossref","unstructured":"Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M et al (2018) Randomized trial of Vonoprazan- Versus PPI-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol","DOI":"10.1111\/jgh.14456"},{"key":"2504_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820966247","volume":"13","author":"M Hojo","year":"2020","unstructured":"Hojo M, Asaoka D, Takeda T, Shimada Y, Matsumoto K, Matsumoto K, et al. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol. 2020;13:1756284820966247.","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"2504_CR16","doi-asserted-by":"publisher","first-page":"e13028","DOI":"10.1111\/hel.13028","volume":"29","author":"T Okimoto","year":"2024","unstructured":"Okimoto T, Ando T, Sasaki M, Ono S, Kobayashi I, Shibayama K, et al. Antimicrobial-resistant Helicobacter pylori in Japan: report of nationwide surveillance for 2018\u20132020. Helicobacter. 2024;29(1):e13028.","journal-title":"Helicobacter"},{"key":"2504_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.908202","volume":"13","author":"Q Ma","year":"2022","unstructured":"Ma Q, Li H, Liao J, Cai Z, Zhang B. Tailored therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Front Pharmacol. 2022;13:908202.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2504_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12933","volume":"27","author":"M Tsuda","year":"2022","unstructured":"Tsuda M, Watanabe Y, Oikawa R, Watanabe R, Higashino M, Kubo K, et al. Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid. Helicobacter. 2022;27(6):e12933.","journal-title":"Helicobacter"},{"key":"2504_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-026-02379-4","author":"H Isomoto","year":"2024","unstructured":"Isomoto H, Shimoyama T, Ito M, Osaki T, Toyoshima O, Matsuzaki J, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition. J Gastroenterol. 2024. https:\/\/doi.org\/10.1007\/s00535-026-02379-4.","journal-title":"J Gastroenterol"},{"issue":"Suppl 2","key":"2504_CR20","first-page":"S171","volume":"23","author":"T Kawai","year":"2008","unstructured":"Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol. 2008;23(Suppl 2):S171\u20134.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2504_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/infdis\/jit287","volume":"208","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208(7):1123\u201330.","journal-title":"J Infect Dis"},{"issue":"10","key":"2504_CR22","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/ajg.2014.222","volume":"109","author":"CS Park","year":"2014","unstructured":"Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595\u2013602.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2504_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jfma.2021.10.011","volume":"121","author":"MS Hsieh","year":"2022","unstructured":"Hsieh MS, Kuo FC, Wu MC, Wang JW, Liu CJ, Chu NS, et al. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. J Formos Med Assoc. 2022;121(8):1450\u20137.","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"2504_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13094","volume":"29","author":"L Liu","year":"2024","unstructured":"Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, et al. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: systematic review and meta-analyses of randomized controlled trials. Helicobacter. 2024;29(3):e13094.","journal-title":"Helicobacter"},{"key":"2504_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020543","author":"M Murata","year":"2020","unstructured":"Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9020543.","journal-title":"J Clin Med"},{"issue":"6","key":"2504_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019\u201326.","journal-title":"Gut"},{"issue":"3","key":"2504_CR27","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, Megraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608\u201319.","journal-title":"Gastroenterology"},{"key":"2504_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093110","author":"T Furuta","year":"2023","unstructured":"Furuta T, Yamade M, Higuchi T, Takahashi S, Ishida N, Tani S, et al. Expectations for the dual therapy with vonoprazan and amoxicillin for the eradication of H. pylori. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12093110.","journal-title":"J Clin Med"},{"issue":"3","key":"2504_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000504939","volume":"102","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 2021;102(3):319\u201325.","journal-title":"Digestion"},{"issue":"10","key":"2504_CR30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00535-012-0731-8","volume":"48","author":"K Murakami","year":"2013","unstructured":"Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48(10):1128\u201335.","journal-title":"J Gastroenterol"},{"issue":"3","key":"2504_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/jgh.12442","volume":"29","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2014;29(3):487\u201393.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2504_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/hel.12286","volume":"21","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, et al. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter. 2016;21(4):286\u201394.","journal-title":"Helicobacter"},{"issue":"3","key":"2504_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/2050640615618043","volume":"4","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United Eur Gastroenterol J. 2016;4(3):380\u20137.","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"2504_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/jgh.14456","volume":"34","author":"S Sue","year":"2019","unstructured":"Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34(4):686\u201392.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2504_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/apt.14849","volume":"48","author":"T Furuta","year":"2018","unstructured":"Furuta T, Baba S, Yamade M, Uotani T, Kagami T, Suzuki T, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther. 2018;48(3):370\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"2504_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12374","author":"S Ono","year":"2017","unstructured":"Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017. https:\/\/doi.org\/10.1111\/hel.12374.","journal-title":"Helicobacter"},{"key":"2504_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2019802","author":"S Sue","year":"2017","unstructured":"Sue S, Suzuki N, Shibata W, Sasaki T, Yamada H, Kaneko H, et al. First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin. Gastroenterol Res Pract. 2017. https:\/\/doi.org\/10.1155\/2017\/2019802.","journal-title":"Gastroenterol Res Pract"},{"issue":"2","key":"2504_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jgh3.12492","volume":"5","author":"S Sue","year":"2021","unstructured":"Sue S, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. JGH Open. 2021;5(2):307\u201311.","journal-title":"JGH Open"},{"issue":"6","key":"2504_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","volume":"53","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 2014;53(6):571\u20135.","journal-title":"Intern Med"},{"issue":"6","key":"2504_CR40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/2050640616688995","volume":"5","author":"H Mori","year":"2017","unstructured":"Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients. United Eur Gastroenterol J. 2017;5(6):796\u2013804.","journal-title":"United Eur Gastroenterol J"},{"issue":"Suppl 1","key":"2504_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1046\/j.1365-2036.2000.014s1216.x","volume":"14","author":"T Azuma","year":"2000","unstructured":"Azuma T, Ito S, Suto H, Ito Y, Miyaji H, Yamazaki Y, et al. Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. Aliment Pharmacol Ther. 2000;14(Suppl 1):216\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2504_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5009\/gnl.2011.5.4.447","volume":"5","author":"N Furusyo","year":"2011","unstructured":"Furusyo N, Walaa AH, Eiraku K, Toyoda K, Ogawa E, Ikezaki H, et al. Treatment for eradication of Helicobacter pylori infection among chronic hepatitis C patients. Gut Liver. 2011;5(4):447\u201353.","journal-title":"Gut Liver"},{"issue":"8","key":"2504_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.kjms.2016.05.012","volume":"32","author":"CE Tsai","year":"2016","unstructured":"Tsai CE, Liang CM, Lee CH, Kuo YH, Wu KL, Chiu YC, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32(8):397\u2013402.","journal-title":"Kaohsiung J Med Sci"},{"issue":"10","key":"2504_CR44","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1046\/j.1365-2036.2003.01527.x","volume":"17","author":"BS Sheu","year":"2003","unstructured":"Sheu BS, Huang JJ, Yang HB, Huang AH, Wu JJ. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. Aliment Pharmacol Ther. 2003;17(10):1283\u201390.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2504_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10157-010-0319-7","volume":"14","author":"WC Chang","year":"2010","unstructured":"Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, et al. Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. Clin Exp Nephrol. 2010;14(5):469\u201373.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"2504_CR46","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajg.2011.07.004","volume":"12","author":"M Seyyedmajidi","year":"2011","unstructured":"Seyyedmajidi M, Falaknazi K, Mirsattari D, Zojaji H, Roshani M, Lahmi F, et al. Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: a randomised clinical trial. Arab J Gastroenterol. 2011;12(3):150\u20133.","journal-title":"Arab J Gastroenterol"},{"key":"2504_CR47","doi-asserted-by":"publisher","first-page":"3762194","DOI":"10.1155\/2017\/3762194","volume":"2017","author":"CM Liang","year":"2017","unstructured":"Liang CM, Chiu CH, Wang HM, Tai WC, Yao CC, Tsai CE, et al. First-line Helicobacter pylori eradication in patients with chronic kidney diseases in Taiwan. Biomed Res Int. 2017;2017:3762194.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2504_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000484981","volume":"97","author":"S Sahara","year":"2018","unstructured":"Sahara S, Sugimoto M, Ichikawa H, Kagami T, Sakao Y, Ohashi N, et al. Efficacy of reduced dosage of amoxicillin in an eradication therapy for Helicobacter pylori infection in patients on hemodialysis: a randomized controlled trial. Digestion. 2018;97(2):163\u20139.","journal-title":"Digestion"},{"issue":"3","key":"2504_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000022000","volume":"44","author":"A Pilotto","year":"1998","unstructured":"Pilotto A, Franceschi M, Di Mario F, Leandro G, Bozzola L, Valerio G. The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease. Gerontology. 1998;44(3):153\u20138.","journal-title":"Gerontology"},{"key":"2504_CR50","doi-asserted-by":"publisher","first-page":"1121947","DOI":"10.3389\/fcimb.2023.1121947","volume":"13","author":"H Gong","year":"2023","unstructured":"Gong H, Xu HM, Zhang DK. Focusing on Helicobacter pylori infection in the elderly. Front Cell Infect Microbiol. 2023;13:1121947.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"2504_CR51","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1111\/hel.13125","volume":"29","author":"E Iwata","year":"2024","unstructured":"Iwata E, Sugimoto M, Asaoka D, Hojo M, Ito M, Kitazawa N, et al. Characteristics of Helicobacter pylori eradication therapy in patients 80 years or Older living in a metropolitan area: a multicenter retrospective study. Helicobacter. 2024;29(4):13125.","journal-title":"Helicobacter"},{"issue":"30","key":"2504_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016619","volume":"98","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Joshita S, Yamamoto C, Yanagisawa T, Miyazawa T, Miyazawa M, et al. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection. Medicine (Baltimore). 2019;98(30):e16619.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2504_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12713","volume":"25","author":"Q Ye","year":"2020","unstructured":"Ye Q, Shao X, Shen R, Chen D, Shen J. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12713.","journal-title":"Helicobacter"},{"key":"2504_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15572","author":"T Horii","year":"2021","unstructured":"Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R, Kusano C, et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1111\/jgh.15572.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2504_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13077","volume":"29","author":"J Chen","year":"2024","unstructured":"Chen J, Zhang Y, Min H, Zhi J, Ma S, Dong H, et al. Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication. Helicobacter. 2024;29(2):e13077.","journal-title":"Helicobacter"},{"issue":"1","key":"2504_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-025-00682-8","volume":"17","author":"JL Guan","year":"2025","unstructured":"Guan JL, Xu TT, Lin Y, Mo YS, He BY, Han YY, et al. High-dose dual therapy for Helicobacter pylori eradication inducing less impact on the gut microbiota. Gut Pathog. 2025;17(1):7.","journal-title":"Gut Pathog"},{"issue":"14","key":"2504_CR57","first-page":"6736","volume":"27","author":"XF Bai","year":"2023","unstructured":"Bai XF, Tian D, Wang TY, Shu JC, He YJ, Zhu MJ. The impact of probiotics on gut microbiota in the eradication of Helicobacter pylori infection: a systematic review. Eur Rev Med Pharmacol Sci. 2023;27(14):6736\u201343.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"Suppl 1","key":"2504_CR58","first-page":"S54","volume":"31","author":"M Koch","year":"1999","unstructured":"Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol. 1999;31(Suppl 1):S54-62.","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"1","key":"2504_CR59","first-page":"43","volume":"30","author":"G Bianchi Porro","year":"1998","unstructured":"Bianchi Porro G, Lazzaroni M, Petrillo M, Manzionna G, Montrone F, Caruso I. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998;30(1):43\u20137.","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"22","key":"2504_CR60","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","volume":"334","author":"AS Taha","year":"1996","unstructured":"Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334(22):1435\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"2504_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","volume":"3","author":"B Scally","year":"2018","unstructured":"Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231\u201341.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2504_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S1590-8658(00)80402-8","volume":"32","author":"M Koch","year":"2000","unstructured":"Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis. 2000;32(2):138\u201351.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"2504_CR63","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2036.2012.05133.x","volume":"36","author":"K Sugano","year":"2012","unstructured":"Sugano K, Kinoshita Y, Miwa H, Takeuchi T, Esomeprazole NPSG. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther. 2012;36(2):115\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2504_CR64","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00535-012-0541-z","volume":"47","author":"K Sugano","year":"2012","unstructured":"Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47(5):540\u201352.","journal-title":"J Gastroenterol"},{"issue":"9573","key":"2504_CR65","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","volume":"369","author":"FK Chan","year":"2007","unstructured":"Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369(9573):1621\u20136.","journal-title":"Lancet"},{"issue":"6","key":"2504_CR66","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67(6):1042\u201351.","journal-title":"Gut"},{"issue":"5","key":"2504_CR67","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14740338.2023.2136163","volume":"22","author":"T Kawai","year":"2023","unstructured":"Kawai T, Suzuki C, Honda Y, Fernandez JL. Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study. Expert Opin Drug Saf. 2023;22(5):425\u201331.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2504_CR68","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1053\/j.gastro.2014.06.007","volume":"147","author":"GM Masclee","year":"2014","unstructured":"Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-92 e9 (quiz e13\u20134).","journal-title":"Gastroenterology"},{"issue":"3","key":"2504_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/ar2207","volume":"9","author":"HE Vonkeman","year":"2007","unstructured":"Vonkeman HE, Fernandes RW, van der Palen J, van Roon EN, van de Laar MA. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther. 2007;9(3):R52.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2504_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","volume":"152","author":"JJ Sung","year":"2010","unstructured":"Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1\u20139.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2504_CR71","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ajg.2012.87","volume":"107","author":"CP Liu","year":"2012","unstructured":"Liu CP, Chen WC, Lai KH, Mar GY, Lin SY, Ger LP, et al. Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. Am J Gastroenterol. 2012;107(7):1022\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2504_CR72","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1111\/j.1572-0241.2008.01995.x","volume":"103","author":"N Yeomans","year":"2008","unstructured":"Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Racz I, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465\u201373.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2504_CR73","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/hrt.2010.217547","volume":"97","author":"JM Scheiman","year":"2011","unstructured":"Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97(10):797\u2013802.","journal-title":"Heart"},{"issue":"2","key":"2504_CR74","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind placebo-controlled trial. Gastroenterology. 2019;157(2):403\u2013125.","journal-title":"Gastroenterology"},{"issue":"5","key":"2504_CR75","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ahj.2011.08.007","volume":"162","author":"P Tunggal","year":"2011","unstructured":"Tunggal P, Ng FH, Lam KF, Chan FK, Lau YK. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J. 2011;162(5):870\u20134.","journal-title":"Am Heart J"},{"issue":"3","key":"2504_CR76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/ajg.2011.385","volume":"107","author":"FH Ng","year":"2012","unstructured":"Ng FH, Tunggal P, Chu WM, Lam KF, Li A, Chan K, et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol. 2012;107(3):389\u201396.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2504_CR77","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1253\/circj.CJ-12-0511","volume":"76","author":"H Yano","year":"2012","unstructured":"Yano H, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. Circ J. 2012;76(11):2673\u201380.","journal-title":"Circ J"},{"issue":"1","key":"2504_CR78","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2020.02.012","volume":"76","author":"K Tsujita","year":"2020","unstructured":"Tsujita K, Deguchi H, Uda A, Sugano K. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study. J Cardiol. 2020;76(1):51\u20137.","journal-title":"J Cardiol"},{"issue":"6","key":"2504_CR79","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00535-011-0397-7","volume":"46","author":"K Sugano","year":"2011","unstructured":"Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011;46(6):724\u201335.","journal-title":"J Gastroenterol"},{"issue":"11","key":"2504_CR80","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00535-012-0588-x","volume":"47","author":"T Sanuki","year":"2012","unstructured":"Sanuki T, Fujita T, Kutsumi H, Hayakumo T, Yoshida S, Inokuchi H, et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol. 2012;47(11):1186\u201397.","journal-title":"J Gastroenterol"},{"issue":"7","key":"2504_CR81","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/apt.12907","volume":"40","author":"R Iwakiri","year":"2014","unstructured":"Iwakiri R, Higuchi K, Kato M, Fujishiro M, Kinoshita Y, Watanabe T, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2014;40(7):780\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2504_CR82","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/gutjnl-2013-304722","volume":"63","author":"K Sugano","year":"2014","unstructured":"Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014;63(7):1061\u20138.","journal-title":"Gut"},{"issue":"1","key":"2504_CR83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.gastro.2009.09.063","volume":"138","author":"FH Ng","year":"2010","unstructured":"Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82\u20138.","journal-title":"Gastroenterology"},{"issue":"1","key":"2504_CR84","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.gastro.2016.09.006","volume":"152","author":"FK Chan","year":"2017","unstructured":"Chan FK, Kyaw M, Tanigawa T, Higuchi K, Fujimoto K, Cheong PK, et al. Similar efficacy of proton-pump inhibitors vs H2-Receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2017;152(1):105-10 e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"2504_CR85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JCMA.0000000000000465","volume":"84","author":"ZF Tseng","year":"2021","unstructured":"Tseng ZF, Hsu PI, Peng NJ, Kao SS, Tsay FW, Cheng JS, et al. Omeprazole vs famotidine for the prevention of gastroduodenal injury in high-risk users of low-dose aspirin: a randomized controlled trial. J Chin Med Assoc. 2021;84(1):19\u201324.","journal-title":"J Chin Med Assoc"},{"issue":"6","key":"2504_CR86","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","volume":"67","author":"T Kawai","year":"2018","unstructured":"Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033\u201341.","journal-title":"Gut"},{"issue":"26","key":"2504_CR87","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa012877","volume":"346","author":"KC Lai","year":"2002","unstructured":"Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"2504_CR88","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.clinthera.2004.10.002","volume":"26","author":"JL Goldstein","year":"2004","unstructured":"Goldstein JL, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther. 2004;26(10):1637\u201343.","journal-title":"Clin Ther"},{"issue":"3","key":"2504_CR89","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2036.2010.04378.x","volume":"32","author":"JL Goldstein","year":"2010","unstructured":"Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32(3):401\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2504_CR90","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/j.1365-2036.2006.02912.x","volume":"23","author":"JL Goldstein","year":"2006","unstructured":"Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther. 2006;23(10):1489\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9605","key":"2504_CR91","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(07)61909-6","volume":"370","author":"V Strand","year":"2007","unstructured":"Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007;370(9605):2138\u201351.","journal-title":"Lancet"},{"issue":"4","key":"2504_CR92","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10557-021-07170-6","volume":"36","author":"SR Lee","year":"2022","unstructured":"Lee SR, Kwon S, Choi EK, Jung JH, Han KD, Oh S, et al. Proton pump inhibitor co-therapy in patients with atrial fibrillation treated with oral anticoagulants and a prior history of upper gastrointestinal tract bleeding. Cardiovasc Drugs Ther. 2022;36(4):679\u201389.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"21","key":"2504_CR93","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2018.17242","volume":"320","author":"WA Ray","year":"2018","unstructured":"Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320(21):2221\u201330.","journal-title":"JAMA"},{"issue":"3","key":"2504_CR94","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/a-1369-5274","volume":"53","author":"IM Gralnek","year":"2021","unstructured":"Gralnek IM, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. Endoscopy. 2021;53(3):300\u201332.","journal-title":"Endoscopy"},{"issue":"9","key":"2504_CR95","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/apt.13800","volume":"44","author":"FC Martin","year":"2016","unstructured":"Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;44(9):915\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2504_CR96","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00535-010-0207-7","volume":"45","author":"M Hongo","year":"2010","unstructured":"Hongo M, Fujimoto K, Gastric Polyps Study G. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45(6):618\u201324.","journal-title":"J Gastroenterol"},{"issue":"5","key":"2504_CR97","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2024.08.004","volume":"23","author":"N Uemura","year":"2025","unstructured":"Uemura N, Kinoshita Y, Haruma K, Kushima R, Yao T, Akiyama J, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol. 2025;23(5):748-57 e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2504_CR98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10147-022-02253-2","volume":"28","author":"TR Peng","year":"2023","unstructured":"Peng TR, Wu TW, Li CH. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2023;28(1):99\u2013109.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"2504_CR99","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/apt.17360","volume":"57","author":"D Piovani","year":"2023","unstructured":"Piovani D, Tsantes AG, Schunemann HJ, Bonovas S. Meta-analysis: use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther. 2023;57(6):653\u201365.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2504_CR100","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1136\/gut.34.6.762","volume":"34","author":"KE McColl","year":"1993","unstructured":"McColl KE, El-Nujumi AM, Chittajallu RS, Dahill SW, Dorrian CA, El-Omar E, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut. 1993;34(6):762\u20138.","journal-title":"Gut"},{"issue":"4","key":"2504_CR101","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","volume":"55","author":"H Echizen","year":"2016","unstructured":"Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2504_CR102","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17512433.2026.2626454","volume":"19","author":"HM Thuy","year":"2026","unstructured":"Thuy HM, Sugimoto M, Quang PMN, Yamaoka Y. CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Rev Clin Pharmacol. 2026;19(2):133\u201350.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"2504_CR103","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/den.12635","volume":"28","author":"T Kanno","year":"2016","unstructured":"Kanno T, Iijima K, Abe Y, Yagi M, Asonuma S, Ohyauchi M, et al. Helicobacter pylori-negative and non-steroidal anti-inflammatory drugs-negative idiopathic peptic ulcers show refractoriness and high recurrence incidence: multicenter follow-up study of peptic ulcers in Japan. Dig Endosc. 2016;28(5):556\u201363.","journal-title":"Dig Endosc"},{"issue":"11","key":"2504_CR104","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1080\/00365521.2019.1679247","volume":"54","author":"MP Dore","year":"2019","unstructured":"Dore MP, Soro S, Niolu C, Longo NP, Bibbo S, Manca A, et al. Clinical features and natural history of idiopathic peptic ulcers: a retrospective case-control study. Scand J Gastroenterol. 2019;54(11):1315\u201321.","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"2504_CR105","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00535-019-01587-5","volume":"54","author":"K Sugawara","year":"2019","unstructured":"Sugawara K, Koizumi S, Horikawa Y, Mimori N, Tsuji T, Ishii H, et al. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan. J Gastroenterol. 2019;54(11):963\u201371.","journal-title":"J Gastroenterol"},{"issue":"7","key":"2504_CR106","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1053\/j.gastro.2005.03.026","volume":"128","author":"LC Hung","year":"2005","unstructured":"Hung LC, Ching JY, Sung JJ, To KF, Hui AJ, Wong VW, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology. 2005;128(7):1845\u201350.","journal-title":"Gastroenterology"},{"issue":"2","key":"2504_CR107","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/j.gastro.2009.05.006","volume":"137","author":"GL Wong","year":"2009","unstructured":"Wong GL, Wong VW, Chan Y, Ching JY, Au K, Hui AJ, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology. 2009;137(2):525\u201331.","journal-title":"Gastroenterology"},{"issue":"2","key":"2504_CR108","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5009\/gnl.2013.7.2.175","volume":"7","author":"H Yoon","year":"2013","unstructured":"Yoon H, Kim SG, Jung HC, Song IS. High recurrence rate of idiopathic peptic ulcers in long-term follow-up. Gut Liver. 2013;7(2):175\u201381.","journal-title":"Gut Liver"},{"issue":"4","key":"2504_CR109","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/gutjnl-2019-318715","volume":"69","author":"GLH Wong","year":"2020","unstructured":"Wong GLH, Lau LHS, Ching JYL, Tse YK, Ling RHY, Wong VWS, et al. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. Gut. 2020;69(4):652\u20137.","journal-title":"Gut"},{"issue":"2","key":"2504_CR110","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00270-008-9442-1","volume":"32","author":"ES Jang","year":"2009","unstructured":"Jang ES, Jeong SH, Kim JW, Lee SH, Yoon CJ, Kang SG. A case of acute ischemic duodenal ulcer associated with superior mesenteric artery dissection after transarterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2009;32(2):367\u201370.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"2504_CR111","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clinre.2016.06.004","volume":"41","author":"A Peixoto","year":"2017","unstructured":"Peixoto A, Goncalves R, Silva M, Paiva D, Lopes J, Macedo G. Extensive ulcerative duodenitis caused by ischemia. Clin Res Hepatol Gastroenterol. 2017;41(2):119\u201320.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"2504_CR112","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/den.14160","volume":"34","author":"T Matsuhashi","year":"2022","unstructured":"Matsuhashi T, Fukuda S, Abe Y, Mikami T, Tatsuta T, Hikichi T, et al. Nature and treatment outcomes of bleeding post-bulbar duodenal ulcers. Dig Endosc. 2022;34(5):984\u201393.","journal-title":"Dig Endosc"},{"issue":"2","key":"2504_CR113","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000519293","volume":"103","author":"H Sekiguchi","year":"2022","unstructured":"Sekiguchi H, Shinozaki S, Takezawa T, Osawa H, Miura Y, Lefor AK, et al. Long-term outcomes in patients with post-bulbar ulcer bleeding compared to bulbar ulcer bleeding in the duodenum. Digestion. 2022;103(2):126\u201332.","journal-title":"Digestion"},{"issue":"6","key":"2504_CR114","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/den.13781","volume":"32","author":"A Shoji","year":"2020","unstructured":"Shoji A, Shichijo S, Fukutake N. Endoscopic naso-biliary and -pancreatic duct drainage for refractory post-bulbar duodenal ulcer bleeding. Dig Endosc. 2020;32(6):999.","journal-title":"Dig Endosc"},{"issue":"5","key":"2504_CR115","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12700","volume":"25","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Overby A, Michimae H, Matsui H, Takahashi S, Mabe K, et al. PCR analysis and specific immunohistochemistry revealing a high prevalence of non-Helicobacter pylori Helicobacters in Helicobacter pylori-negative gastric disease patients in Japan: high susceptibility to an Hp eradication regimen. Helicobacter. 2020;25(5):e12700.","journal-title":"Helicobacter"},{"issue":"1","key":"2504_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01331-x","volume":"20","author":"S Shafaie","year":"2020","unstructured":"Shafaie S, Kaboosi H, Peyravii Ghadikolaii F. Prevalence of non Helicobacter pylori gastric Helicobacters in Iranian dyspeptic patients. BMC Gastroenterol. 2020;20(1):190.","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"2504_CR117","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/apt.17488","volume":"57","author":"E Taillieu","year":"2023","unstructured":"Taillieu E, De Witte C, De Schepper H, Van Moerkercke W, Rutten S, Michiels S, et al. Clinical significance and impact of gastric non-Helicobacter pyloriHelicobacter species in gastric disease. Aliment Pharmacol Ther. 2023;57(12):1432\u201344.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2504_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70051","volume":"30","author":"M Sugimoto","year":"2025","unstructured":"Sugimoto M, Rimbara E, Murata M, Yamaoka Y. Roles of gastric non-Helicobacter pyloriHelicobacter species in gastric disease development: a review. Helicobacter. 2025;30(3):e70051.","journal-title":"Helicobacter"},{"issue":"6","key":"2504_CR119","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3201\/eid3106.241315","volume":"31","author":"K Tokunaga","year":"2025","unstructured":"Tokunaga K, Rimbara E, Tsukadaira T, Mabe K, Yahara K, Suzuki H, et al. Prospective multicenter surveillance of non-H. pylori Helicobacter infections during medical checkups, Japan. Emerg Infect Dis. 2025;31(6):1121\u201330.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"2504_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106522","volume":"26","author":"H Matsui","year":"2023","unstructured":"Matsui H, Rimbara E, Suzuki M, Tokunaga K, Suzuki H, Sano M, et al. Development of serological assays to identify Helicobacter suis and H. pylori infections. iScience. 2023;26(4):106522.","journal-title":"iScience"},{"issue":"34","key":"2504_CR121","first-page":"1195","volume":"47","author":"A Janke","year":"2000","unstructured":"Janke A, Stasiewicz J, Namiot Z, Szalaj W. Treatment of the gastric stump ulcer: an open study with five drugs. Hepatogastroenterology. 2000;47(34):1195\u20138.","journal-title":"Hepatogastroenterology"},{"issue":"4","key":"2504_CR122","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/00042737-199704000-00010","volume":"9","author":"MK Leivonen","year":"1997","unstructured":"Leivonen MK, Haglund CH, Nordling SF. Helicobacter pylori infection after partial gastrectomy for peptic ulcer and its role in relapsing disease. Eur J Gastroenterol Hepatol. 1997;9(4):371\u20134.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"2504_CR123","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1572-0241.1998.00279.x","volume":"93","author":"YT Lee","year":"1998","unstructured":"Lee YT, Sung JJ, Choi CL, Chan FK, Ng EK, Ching JY, et al. Ulcer recurrence after gastric surgery: is Helicobacter pylori the culprit? Am J Gastroenterol. 1998;93(6):928\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2504_CR124","first-page":"127","volume":"37","author":"D Schilling","year":"1999","unstructured":"Schilling D, Adamek HE, Wilke J, Schauwecker P, Martin WR, Arnold JC, et al. Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. A prospective evaluation of Helicobacter pylori infection on 50 resected patients compared with matched nonresected controls. Z Gastroenterol. 1999;37(2):127\u201332.","journal-title":"Z Gastroenterol"},{"issue":"59","key":"2504_CR125","first-page":"1551","volume":"51","author":"WH Huang","year":"2004","unstructured":"Huang WH, Wang HH, Wu WW, Lai HC, Hsu CH, Cheng KS. Helicobacter pylori infection in patients with ulcer recurrence after partial gastrectomy. Hepatogastroenterology. 2004;51(59):1551\u20133.","journal-title":"Hepatogastroenterology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02504-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:02:14Z","timestamp":1790452934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02504-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":125,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2504"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02504-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript is listed as follows: (1) personal remuneration (honoraria, consulting fees, advisory roles, etc.) AbbVie Inc.; AstraZeneca K.K.; ASKA Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; EA Pharma; Eisai Co., Ltd.; Gilead Sciences Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Toray Industries Inc,. (2) institutional research funding or other support (commercial\/academic cooperation). Nobel pharma Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}